ADMA Biologics to Announce Q4 Earnings on February 25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Should l Buy ADMA?
Source: seekingalpha
- Earnings Announcement: ADMA Biologics is set to release its Q4 2023 earnings report on February 25 after market close, with a consensus EPS estimate of $0.20, indicating stable profitability for the company.
- Revenue Growth Expectations: The consensus revenue estimate stands at $139.8 million, reflecting an 18.9% year-over-year increase, suggesting sustained demand in the biopharmaceutical sector, which could bolster future investment confidence.
- Market Reaction Anticipation: As the earnings report approaches, investor expectations are high for ADMA's performance, particularly given the company's ongoing efforts to expand its product line and market share, which may positively influence stock prices.
- Industry Outlook Analysis: ADMA's growth potential in the biopharmaceutical industry is closely tied to the launch of its innovative products, and if the earnings results exceed expectations, it could further solidify its competitive position in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics to Announce Q4 Earnings on February 25
- Earnings Announcement: ADMA Biologics is set to release its Q4 2023 earnings report on February 25 after market close, with a consensus EPS estimate of $0.20, indicating stable profitability for the company.
- Revenue Growth Expectations: The consensus revenue estimate stands at $139.8 million, reflecting an 18.9% year-over-year increase, suggesting sustained demand in the biopharmaceutical sector, which could bolster future investment confidence.
- Market Reaction Anticipation: As the earnings report approaches, investor expectations are high for ADMA's performance, particularly given the company's ongoing efforts to expand its product line and market share, which may positively influence stock prices.
- Industry Outlook Analysis: ADMA's growth potential in the biopharmaceutical industry is closely tied to the launch of its innovative products, and if the earnings results exceed expectations, it could further solidify its competitive position in the market.
See More
Ranger Investment Management Increases Solaris Holdings
- Share Increase: On February 13, 2026, Ranger Investment Management disclosed an increase of 197,073 shares in Solaris Energy Infrastructure, representing an estimated $9.53 million trade, indicating strong confidence in the company.
- Market Value Growth: The quarter-end value of Solaris increased by $11.62 million due to both the share addition and stock price movement, reflecting robust performance and market recognition in the energy infrastructure sector.
- Financial Performance: Solaris reported $167 million in third-quarter revenue, a 12% sequential increase, with net income of $25 million, showcasing strong growth potential in energy infrastructure tied to electrification and data centers.
- Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance, demonstrating confidence in future growth and an aggressive capital expenditure plan.
See More
Ranger Investment Management Increases Solaris Shares
- Share Increase: Ranger Investment Management acquired 197,073 shares of Solaris in Q4 2026, with an estimated trade value of $9.53 million, reflecting the firm's confidence in Solaris's growth potential.
- Position Value Growth: The quarter-end value of Solaris's position rose by $11.62 million, indicating not only an increase in shares but also a positive impact from stock price appreciation, further solidifying Ranger's investment strategy.
- Strong Financial Performance: Solaris reported $167 million in revenue for Q3, a 12% sequential increase, with a net income of $25 million, showcasing its robust performance and growth potential in the energy infrastructure market.
- Optimistic Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance of $70 million to $75 million, indicating strong confidence in future performance.
See More
ADMA Biologics CEO to Present at J.P. Morgan Healthcare Conference
- Conference Participation: ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM PT, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor interest.
- Product Portfolio: ADMA currently markets three FDA-approved plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, highlighting the company's market positioning and expertise in niche medical areas.
- R&D Initiatives: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, indicating the company's ongoing commitment to innovative drug development aimed at meeting the needs of specific patient populations.
- Manufacturing Capabilities: ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, ensuring the quality and stability of its biologics supply, thereby reinforcing its competitive advantage in the biopharmaceutical market.
See More
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
See More
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
See More
ADMA Biologics to Announce Q4 Earnings on February 25
- Earnings Announcement: ADMA Biologics is set to release its Q4 2023 earnings report on February 25 after market close, with a consensus EPS estimate of $0.20, indicating stable profitability for the company.
- Revenue Growth Expectations: The consensus revenue estimate stands at $139.8 million, reflecting an 18.9% year-over-year increase, suggesting sustained demand in the biopharmaceutical sector, which could bolster future investment confidence.
- Market Reaction Anticipation: As the earnings report approaches, investor expectations are high for ADMA's performance, particularly given the company's ongoing efforts to expand its product line and market share, which may positively influence stock prices.
- Industry Outlook Analysis: ADMA's growth potential in the biopharmaceutical industry is closely tied to the launch of its innovative products, and if the earnings results exceed expectations, it could further solidify its competitive position in the market.
See More
Ranger Investment Management Increases Solaris Holdings
- Share Increase: On February 13, 2026, Ranger Investment Management disclosed an increase of 197,073 shares in Solaris Energy Infrastructure, representing an estimated $9.53 million trade, indicating strong confidence in the company.
- Market Value Growth: The quarter-end value of Solaris increased by $11.62 million due to both the share addition and stock price movement, reflecting robust performance and market recognition in the energy infrastructure sector.
- Financial Performance: Solaris reported $167 million in third-quarter revenue, a 12% sequential increase, with net income of $25 million, showcasing strong growth potential in energy infrastructure tied to electrification and data centers.
- Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance, demonstrating confidence in future growth and an aggressive capital expenditure plan.
See More
Ranger Investment Management Increases Solaris Shares
- Share Increase: Ranger Investment Management acquired 197,073 shares of Solaris in Q4 2026, with an estimated trade value of $9.53 million, reflecting the firm's confidence in Solaris's growth potential.
- Position Value Growth: The quarter-end value of Solaris's position rose by $11.62 million, indicating not only an increase in shares but also a positive impact from stock price appreciation, further solidifying Ranger's investment strategy.
- Strong Financial Performance: Solaris reported $167 million in revenue for Q3, a 12% sequential increase, with a net income of $25 million, showcasing its robust performance and growth potential in the energy infrastructure market.
- Optimistic Future Outlook: Management raised fourth-quarter Adjusted EBITDA guidance to $65 million to $70 million and initiated first-quarter 2026 guidance of $70 million to $75 million, indicating strong confidence in future performance.
See More
ADMA Biologics CEO to Present at J.P. Morgan Healthcare Conference
- Conference Participation: ADMA Biologics CEO Adam Grossman will present at the J.P. Morgan Healthcare Conference on January 12, 2026, at 9:45 AM PT, showcasing the company's latest advancements in biopharmaceuticals, which is expected to attract investor interest.
- Product Portfolio: ADMA currently markets three FDA-approved plasma-derived biologics for treating immune deficiencies and preventing certain infectious diseases, highlighting the company's market positioning and expertise in niche medical areas.
- R&D Initiatives: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumonia, indicating the company's ongoing commitment to innovative drug development aimed at meeting the needs of specific patient populations.
- Manufacturing Capabilities: ADMA operates an FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida, ensuring the quality and stability of its biologics supply, thereby reinforcing its competitive advantage in the biopharmaceutical market.
See More
Stonepine Capital Fully Exits ANI Pharmaceuticals, Reporting $2.52 Million Loss
- Full Exit: Stonepine Capital sold all 38,597 shares of ANI Pharmaceuticals in Q3, valued at approximately $2.52 million, marking a complete exit from the company as of September 30.
- Market Performance: Despite Stonepine's exit, ANI Pharmaceuticals' stock has risen 49% over the past year, currently priced at $82.41, significantly outperforming the S&P 500's 15% increase during the same period, indicating strong market competitiveness.
- Financial Growth: ANI Pharmaceuticals reported a 54% year-over-year revenue surge to $227.8 million in the latest quarter, with adjusted EBITDA jumping nearly 70% to $59.6 million, prompting management to raise full-year revenue guidance to $873 million.
- Investment Strategy Shift: The exit by Stonepine does not reflect a lack of confidence in ANI but rather a capital rotation, indicating a preference for earlier-stage biotech investments, which suggests a cautious outlook on ANI's future growth potential.
See More
Eight Stock Selections to Capitalize on a Robust Sector of the Market
Healthcare Sector Valuation: The U.S. healthcare sector is currently attractively priced, with a forward price/earnings (P/E) ratio of 18.2, appealing to investors wary of the overall market's high valuations.
Comparison with S&P 500: The healthcare sector's forward P/E is a 12% premium over its 10-year average, while the broader S&P 500 has a forward P/E of 22.4, which is a 19% premium to its historical average.
See More
